Zacks Investment Research upgraded shares of Omeros (NASDAQ:OMER) from a sell rating to a hold rating in a research note released on Saturday, Zacks.com reports.

According to Zacks, “Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros’ most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. “

Several other equities research analysts have also recently issued reports on OMER. ValuEngine upgraded Omeros from a hold rating to a buy rating in a research note on Thursday, August 1st. Wedbush reiterated a neutral rating and issued a $18.00 price target on shares of Omeros in a research note on Monday, July 15th. HC Wainwright set a $35.00 price target on Omeros and gave the company a buy rating in a research note on Tuesday, May 28th. BidaskClub upgraded Omeros from a sell rating to a hold rating in a research note on Tuesday, July 30th. Finally, Cantor Fitzgerald initiated coverage on Omeros in a research note on Monday, May 6th. They set an overweight rating and a $26.00 target price for the company. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $25.80.

Shares of OMER stock opened at $19.19 on Friday. The company has a market capitalization of $925.27 million, a PE ratio of -8.64 and a beta of 2.98. The company has a 50 day moving average of $15.60. Omeros has a 1 year low of $10.30 and a 1 year high of $27.00.

Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.15. The company had revenue of $26.80 million during the quarter, compared to the consensus estimate of $25.33 million. The company’s quarterly revenue was up 1476.5% on a year-over-year basis. During the same quarter last year, the firm posted ($0.70) earnings per share. As a group, research analysts expect that Omeros will post -1.68 EPS for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp increased its holdings in shares of Omeros by 0.4% in the 4th quarter. Bank of New York Mellon Corp now owns 214,955 shares of the biopharmaceutical company’s stock valued at $2,394,000 after acquiring an additional 817 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Omeros by 7.5% in the 4th quarter. Geode Capital Management LLC now owns 516,632 shares of the biopharmaceutical company’s stock valued at $5,755,000 after acquiring an additional 35,974 shares during the last quarter. Two Sigma Advisers LP increased its holdings in shares of Omeros by 81.2% in the 4th quarter. Two Sigma Advisers LP now owns 39,500 shares of the biopharmaceutical company’s stock valued at $440,000 after acquiring an additional 17,700 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Omeros by 5.8% in the 4th quarter. Bank of America Corp DE now owns 78,352 shares of the biopharmaceutical company’s stock valued at $873,000 after acquiring an additional 4,302 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY increased its holdings in shares of Omeros by 417.4% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 16,004 shares of the biopharmaceutical company’s stock valued at $178,000 after acquiring an additional 12,911 shares during the last quarter. Hedge funds and other institutional investors own 51.64% of the company’s stock.

About Omeros

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Featured Story: How to start trading in the forex market?

Get a free copy of the Zacks research report on Omeros (OMER)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.